Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Thyroid Neoplasms 1Teratoma, Ovarian 1Struma Ovarii 1Squamous Cell Carcinoma of Head and Neck 1Ovarian Neoplasms 1Oligodendroglioma 1Head and Neck Neoplasms 1Glioblastoma 1Carcinoma, Squamous Cell 1Carcinoma 1Astrocytoma 1

Interventions

Cisplatin 12Cetuximab 9pembrolizumab 7Radiotherapy 7Fluorouracil 6Carboplatin 5Radiotherapy, Intensity-Modulated 4Nivolumab 4epacadostat 3Radiation 3Docetaxel 3Venlafaxine Hydrochloride 2Surveys and Questionnaires 2Panitumumab 2Paclitaxel 2Ketamine 2zimberelimab 1vandetanib 1tislelizumab 1temsirolimus 1ruxolitinib 1plerixafor 1nimotuzumab 1linrodostat 1fosbretabulin 1fluoromisonidazole 1fludarabine phosphate 1fludarabine 1elgemtumab 1ebselen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Head and Neck Neoplasms × DNA × Clear all
NCT02211027 2017-09-07

Biological Vaccine: Semi-allogeneic Human Fibroblasts (MRC-5) Transfected With DNA

University of Pittsburgh

Phase 1 Withdrawn
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Carcinoma, Squamous Cell, Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡